伊布利特转复心房颤动的临床疗效及安全性评价  

Clinical evaluation of efficacy and safety of intravenous ibutilide on patients with atrial fibrillation

作　　者：纪焕文[1] 

机构地区：[1]河南省郑州市中心医院心内一科,河南郑州450000

出　　处：《中外医疗》2012年第18期16-16,18,共2页China & Foreign Medical Treatment

摘　　要：目的观察新型Ⅲ类抗心律失常药伊布利特转复心房颤动的疗效及安全性。方法以38例房颤患者为观察对象,将其按1:1随机分为观察组和对照组,观察组静脉注射伊布利特治疗,观察组给予普罗帕酮静脉注射治疗。观察并比较两组患者给药后90min内的房颤的转复率及24h内的不良反应。结果给药后90min内,观察组和对照组转复率分别为57.89%(11/19)和31.58%(6/19),平均转复时间分别为(11.65±5.23)min和(26.21±13.89)min,两组转复率和转复时间差异均具有统计学意义(P<0.05)。两组患者均未出现严重不良反应。观察组24h内不良反应发生率为5.26%(1/19)。对照组不良反应发生率为26.32%(5/19例),观察组不良反应发生率明显低于对照组,差异具有统计学意义(P<0.05)。结论伊布利特转复心房颤动起效迅速、疗效显著、安全可靠。Objective To observe converting efficacy and safety of intravenous ibutilide on atrial fibrillation patients. Methods 38 AF patients were divided into two groups ,with 19 patients each. Patients of the group were treated with ibutilide and propafenone individually . Clinical efficacy were evaluated after 90 minutes and adverse reaction were observed after 24 hours of intravenous injection. Results Ibutilide had a higher cardioversion rate （57.89%） than propafenone （31.58%）with statistical significance（P〈 0.05）; The mean converting time of ibutilide group and propafenone group were（11.65±5.23） min and （26.21±13.89） min individu- ally, and the former was significantly shorter than the latter （P〈O.05）;The adverse reaction rate of ibutilide group was 5.26%,which was much lower than that of propafenone group （26.32%）.Conclusion Ibutilide is allegro, effective and safety in converting atrial fibrillation.

关 键 词：心房颤动 伊布利特 普罗帕酮 转复 

分 类 号：R541.75[医药卫生—心血管疾病]